摘要
目的评价莫西沙星、加替沙星对女性尿路感染的临床疗效。方法将299例单纯性、急性、非淋菌性和混合性尿路感染女性患者随机分为莫西沙星组150例和加替沙星组149例,分别口服莫西沙星和加替沙星400mg/d,疗程均为7d。结果莫西沙星组与加替沙星组临床总有效率分别为96.00%和95.30%,病原菌清除率分别为89.89%和87.10%,不良反应率分别为8.00%和8.72%,组间比较均无显著性差异(P>0.05)。结论莫西沙星与加替沙星治疗女性尿路感染安全有效,均可作为第一线药物使用。
Objective To evaluate the clinical efficacy of moxifloxacin and gatifloxacin for treating women＇s urinary tract infection （WUTI）. Methods 299 cases of simple, acute, nongonococcal and compound UTI were randomly assigned to moxifloxacin group（150 cases） and gatifloxacin group （149 cases）, once daily oral 400 mg of moxifloxacin or gatifloxacin, respectively. The treatment course was 7 d. Results The clinical total effective rates in the moxifloxacin and gatifloxacin groups were 96.00% and 95.30%, the bacterial clearance rates were 89.89% and 87.10%, the adverse effect were 8.00% and 8.72% respectively. Conclusion Moxifloxacin and gatifloxacin are all effective and safe in the treatment of WUTI, those drugs may become as first line drugs in treating WUTI.
出处
《中国药业》
CAS
2009年第11期56-57,共2页
China Pharmaceuticals
关键词
莫西沙星
加替沙星
女性尿路感染
临床疗效
moxifloxacin
gatifloxacin
women＇s urinary tract infection
clinical efficacy
